Nuwellis

Historical price data

Nuwellis is a commercial-stage medtech company with a mission to intervene earlier in cardiorenal disease progression through its proprietary, precision ultrafiltration technology. Its core achievement is the commercialization of the Aquadex SmartFlow® system, which is supported by over two decades of clinical evidence demonstrating reductions in hospitalizations, readmissions, and patient complications. The company's strategy focuses on expanding utilization of its single-platform technology across multiple clinical specialties—including heart failure, critical care, and pediatrics—by driving clinical education, securing reimbursement, and demonstrating cost-effectiveness to healthcare systems.

The Aquadex SmartFlow® System, a proprietary extracorporeal ultrafiltration platform for the precise, controlled, and predictable removal of isotonic fluid in patients with diuretic-resistant fluid overload.

Nuwellis competes primarily against standard loop diuretics and, in the device space, against more complex continuous renal replacement therapy (CRRT) machines from larger players like Baxter and Fresenius. Its strategy is to differentiate through simplicity, a dedicated focus on ultrafiltration, and a strong foundation of clinical evidence targeting non-nephrology specialists.